FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib

FDA Approves Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer

FDA Approves First Targeted Therapy for HER2-Low Breast Cancer

FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumors

A Framework for Assessing the Impact of Accelerated Approval

FDA Approves Lisocabtagene Maraleucel for the Second-Line Treatment of Large B-Cell Lymphoma

Dabrafenib/Trametinib Combination Receives FDA Approval for BRAF V600E–Mutated Solid Tumors

FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib

header-info

Jul, 05, 2022

The U.S. Food and Drug Administration (FDA) is warning that results from the phase III DUO clinical trial show a possible increased risk of death with duvelisib compared to ofatumumab among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).